Summary of response rates
| Response . | Cohort, n/n (%) . | ||
|---|---|---|---|
| 45 mg . | 30 mg . | 15 mg . | |
| ≤1% BCR-ABL1IS by 12 mo | 48/93 (51.6) | 33/93 (35.5) | 23/91 (25.3) |
| Mutation status at baseline* | |||
| T315I mutation | 15/25 (60.0) | 5/20 (25.0) | 2/19 (10.5) |
| No T315I mutation | 32/66 (48.5) | 28/73 (38.4) | 21/71 (29.6) |
| Mutation other than T315I | 9/16 (56.3) | 6/15 (40.0) | 6/18 (33.3) |
| No mutation | 23/50 (46.0) | 22/58 (37.9) | 15/53 (28.3) |
| Best response to last prior therapy | |||
| CHR or worse | 27/54 (50) | 11/53 (20.8) | 8/52 (15.4) |
| Better than CHR | 14/28 (50) | 17/29 (58.6) | 9/23 (39.1) |
| Response . | Cohort, n/n (%) . | ||
|---|---|---|---|
| 45 mg . | 30 mg . | 15 mg . | |
| ≤1% BCR-ABL1IS by 12 mo | 48/93 (51.6) | 33/93 (35.5) | 23/91 (25.3) |
| Mutation status at baseline* | |||
| T315I mutation | 15/25 (60.0) | 5/20 (25.0) | 2/19 (10.5) |
| No T315I mutation | 32/66 (48.5) | 28/73 (38.4) | 21/71 (29.6) |
| Mutation other than T315I | 9/16 (56.3) | 6/15 (40.0) | 6/18 (33.3) |
| No mutation | 23/50 (46.0) | 22/58 (37.9) | 15/53 (28.3) |
| Best response to last prior therapy | |||
| CHR or worse | 27/54 (50) | 11/53 (20.8) | 8/52 (15.4) |
| Better than CHR | 14/28 (50) | 17/29 (58.6) | 9/23 (39.1) |
Four patients did not have a mutation test result at baseline.